| $350M | ||
| $172M | ||
| $115M | ||
| $109M | ||
| $107M | ||
| $100M |
Buys | $0 | 0 | 0 |
Sells | $1,694,057 | 6 | 100 |
| Ogden Christopher | Chief Financial Officer | 0 | $0 | 2 | $129,065 | $-129,065 |
| Chu Yu-Waye | Chief Medical Officer | 0 | $0 | 1 | $136,675 | $-136,675 |
| BELVIN MARCIA | SVP, Chief Scientific Officer | 0 | $0 | 1 | $202,273 | $-202,273 |
| McCarthy Sean A. | CEO | 0 | $0 | 2 | $1.23M | $-1.23M |
CytomX Therapeutics, Inc. is a United States-based biopharmaceutical company primarily focused on creating treatments for cancer. The company utilizes its proprietary Probody technology platform to engineer targeted antibody therapeutics for oncological applications. Its robust clinical pipeline includes several notable drug candidates. CX-2009, an antibody-drug conjugate (ADC) designed to target CD166, is currently in Phase II clinical trials for treating breast cancer. Another investigational therapy, CX-2029, has also reached Phase II trials, where it is being evaluated for various cancers such as squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma. Additionally, CytomX is progressing two CTLA-4 Probody therapeutics: BMS-986249, which is undergoing Phase I/II clinical trials for metastatic melanoma, and BMS-986288, in Phase I trials for solid tumors. Beyond these, the company is developing CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, and CX-904, a conditionally activated epidermal growth factor receptor, both aimed at addressing solid tumor conditions. CytomX has forged strategic partnerships with leading pharmaceutical firms, including AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc., to collaboratively advance its Probody therapeutics. The company was founded in 2008 and its main office is located in South San Francisco, California.
Over the last 12 months, insiders at CytomX Therapeutics, Inc. have bought $0 and sold $1.69M worth of CytomX Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at CytomX Therapeutics, Inc. have bought $7,750 and sold $452,873 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,000 shares for transaction amount of $7,750 was made by Jones Elaine V (director) on 2023‑03‑29.
| 2026-06-15 | Sale | Ogden Christopher | Chief Financial Officer | 1,624 0.001% | $3.05 | $4,953 | +11.68% | |
| 2026-03-17 | Sale | McCarthy Sean A. | CEO | 118,969 0.0828% | $6.42 | $764,138 | -33.03% | |
| 2026-03-17 | Sale | BELVIN MARCIA | SVP, Chief Scientific Officer | 31,492 0.0219% | $6.42 | $202,273 | -33.03% | |
| 2026-03-17 | Sale | Ogden Christopher | Chief Financial Officer | 19,323 0.0134% | $6.42 | $124,112 | -33.03% | |
| 2026-03-17 | Sale | Chu Yu-Waye | Chief Medical Officer | 21,279 0.0148% | $6.42 | $136,675 | -33.03% | |
| 2025-11-06 | Sale | McCarthy Sean A. | CEO | 101,793 0.0785% | $4.54 | $461,906 | -3.34% | |
| 2025-06-16 | Sale | McCarthy Sean A. | CEO | 55,511 0.0385% | $2.69 | $149,264 | +54.88% | |
| 2025-06-16 | Sale | BELVIN MARCIA | SVP, Chief Scientific Officer | 13,884 0.0096% | $2.69 | $37,334 | +54.88% | |
| 2025-06-16 | Sale | Ogden Christopher | Chief Financial Officer | 10,614 0.0074% | $2.69 | $28,540 | +54.88% | |
| 2025-06-13 | Sale | Ogden Christopher | Chief Financial Officer | 1,641 0.0011% | $2.95 | $4,841 | +39.45% | |
| 2025-03-18 | Sale | McCarthy Sean A. | CEO | 37,656 0.0466% | $0.60 | $22,556 | +338.96% | |
| 2025-03-18 | Sale | BELVIN MARCIA | SVP, Chief Scientific Officer | 19,512 0.0242% | $0.60 | $11,688 | +338.96% | |
| 2025-03-18 | Sale | Ogden Christopher | Chief Financial Officer | 8,551 0.0106% | $0.60 | $5,122 | +338.96% | |
| 2025-03-18 | Sale | Chu Yu-Waye | Chief Medical Officer | 4,025 0.005% | $0.60 | $2,411 | +338.96% | |
| 2025-03-18 | Sale | ROWLAND LLOYD A | General Counsel | 10,203 0.0126% | $0.60 | $6,112 | +338.96% | |
| 2024-08-20 | Sale | McCarthy Sean A. | CEO | 13,898 0.0176% | $1.23 | $17,082 | -10.08% | |
| 2024-08-20 | Sale | BELVIN MARCIA | SVP, Chief Scientific Officer | 4,181 0.0053% | $1.23 | $5,139 | -10.08% | |
| 2024-08-20 | Sale | ROWLAND LLOYD A | General Counsel | 4,181 0.0053% | $1.23 | $5,139 | -10.08% | |
| 2024-08-20 | Sale | Landau Jeffrey B | Chief Business Officer | 4,181 0.0053% | $1.23 | $5,139 | -10.08% | |
| 2024-08-20 | Sale | Ogden Christopher | Chief Financial Officer | 1,984 0.0025% | $1.23 | $2,439 | -10.08% |
| McCarthy Sean A. | CEO | 1078922 0.4956% | $3.55M | 0 | 38 | |
| BELVIN MARCIA | SVP, Chief Scientific Officer | 300760 0.1382% | $989,500.40 | 0 | 7 | |
| Ogden Christopher | Chief Financial Officer | 295324 0.1357% | $971,615.96 | 0 | 9 | |
| Chu Yu-Waye | Chief Medical Officer | 189446 0.087% | $623,277.34 | 0 | 2 | |
| THIRD ROCK VENTURES LP | 10 percent owner | 5170348 2.375% | $17.01M | 0 | 2 | |
| Canaan IX L.P. | director | 3644381 1.674% | $11.99M | 0 | 29 | |
| SHANNON TIMOTHY M | director | 3244381 1.4903% | $10.67M | 0 | 29 | |
| Flynn James E | 10 percent owner | 671024 0.3082% | $2.21M | 1 | 0 | <0.0001% |
| GLUCK FREDERICK W | director | 271643 0.1248% | $893,705.47 | 1 | 8 | <0.0001% |
| ROWLAND LLOYD A | General Counsel | 120594 0.0554% | $396,754.26 | 1 | 7 | <0.0001% |
| Landau Jeffrey B | Chief Business Officer | 119056 0.0547% | $391,694.24 | 0 | 6 | |
| Peterson Amy C. | EVP, Chief Development Officer | 58433 0.0268% | $192,244.57 | 0 | 2 | |
| Campoy Carlos | Chief Financial Officer | 38224 0.0176% | $125,756.96 | 0 | 2 | |
| HANNAH ALISON L. | Chief Medical Officer | 31898 0.0147% | $104,944.42 | 0 | 1 | |
| STARR KEVIN P | 10 percent owner | 31419 0.0144% | $103,368.51 | 0 | 1 | |
| HUMPHREY RACHEL | Chief Medical Officer | 30234 0.0139% | $99,469.86 | 0 | 2 | |
| TEPPER ROBERT I | 10 percent owner | 29516 0.0136% | $97,107.64 | 0 | 3 | |
| Kavanaugh William Michael | CSO, Head Res.&Non-Clin. Dev. | 13917 0.0064% | $45,786.93 | 1 | 1 | <0.0001% |
| Goeltz II Robert C. | Chief Financial Officer | 9789 0.0045% | $32,205.81 | 0 | 1 | |
| RAY DEBANJAN | Chief Financial Officer | 5928 0.0027% | $19,503.12 | 0 | 19 | |
| Jones Elaine V | director | 5142 0.0024% | $16,917.18 | 1 | 0 | +0.98% |
| LADD CYNTHIA J | Senior VP and General Counsel | 3000 0.0014% | $9,870.00 | 1 | 0 | <0.0001% |
| Exter Neil | director | 0 0% | $0 | 0 | 2 |
$9,654,532 | 101 | -5.65% | $636.61M | |
$5,911,307 | 70 | -1.38% | $643.23M | |
$24,384,691 | 42 | -30.27% | $635.93M | |
$16,169,789 | 40 | 7.44% | $720.96M | |
$1,334,066 | 36 | 6.17% | $660.44M | |
$8,866,498 | 28 | 33.64% | $666.13M | |
$50,191,994 | 27 | 106.80% | $676.33M | |
$59,130,768 | 20 | 24.81% | $645.54M | |
$22,365,077 | 19 | -27.47% | $772.63M | |
$65,698,913 | 15 | -2.42% | $723.54M | |
$1,451,427 | 11 | 3.36% | $866.05M | |
$105,345,724 | 9 | -19.24% | $856.51M | |
$330,467 | 8 | -18.39% | $724.77M | |
$272,024 | 7 | 16.80% | $709.97M | |
CytomX Therapeutics, Inc. (CTMX) | $15,652,720 | 6 | -4.77% | $716.24M |
$88,549,962 | 5 | -16.91% | $688.48M | |
$12,035,408 | 5 | -37.54% | $738.64M | |
$12,750 | 2 | -39.73% | $847.36M | |
$704,400 | 2 | -29.92% | $871.05M |
| Increased Positions | 78 | +71.56% | 38M | +27.75% |
| Decreased Positions | 45 | -41.28% | 31M | -22.92% |
| New Positions | 39 | New | 7M | New |
| Sold Out Positions | 20 | Sold Out | 21M | Sold Out |
| Total Postitions | 142 | +30.28% | 144M | +4.83% |
| Vr Adviser, Llc | $66,136.00 | 9.21% | 15.56M | +2M | +11.39% | 2025-09-30 |
| Fmr Llc | $65,434.00 | 9.11% | 15.4M | +6M | +66.65% | 2025-09-30 |
| Tang Capital Management Llc | $47,029.00 | 6.55% | 11.07M | 0 | 0% | 2025-09-30 |
| Perceptive Advisors Llc | $41,141.00 | 5.73% | 9.68M | +3M | +38.41% | 2025-09-30 |
| Vanguard Group Inc | $38,028.00 | 5.3% | 8.95M | -431,987 | -4.61% | 2025-09-30 |
| Orbimed Advisors Llc | $35,961.00 | 5.01% | 8.46M | 0 | 0% | 2025-09-30 |
| Commodore Capital Lp | $32,692.00 | 4.55% | 7.69M | 0 | 0% | 2025-09-30 |
| Baker Bros. Advisors Lp | $18,066.00 | 2.52% | 4.25M | +766,600 | +22% | 2025-09-30 |
| Point72 Asset Management, L.P. | $17,291.00 | 2.41% | 4.07M | -4M | -49.67% | 2025-09-30 |
| Adar1 Capital Management, Llc | $17,193.00 | 2.39% | 4.05M | +964,000 | +31.28% | 2025-09-30 |